Artemether-lumefantrine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Malaria
Conditions
Malaria, Falciparum
Trial Timeline
Aug 1, 2006 → Mar 1, 2007
NCT ID
NCT00386763About Artemether-lumefantrine
Artemether-lumefantrine is a phase 3 stage product being developed by Novartis for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT00386763. Target conditions include Malaria, Falciparum.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00386763 | Phase 3 | Completed |
| NCT00386750 | Approved | Terminated |
| NCT00709969 | Phase 3 | Completed |
Competing Products
20 competing products in Malaria